guest ::
| Home > Publications Database > Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation. |
| Home > Publications Database > Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation. |
| Journal Article | DZNE-2025-00029 |
; ; ; ; ;
2025
Thieme
Stuttgart [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1055/a-2446-6877
Abstract: This study evaluates the impact of Parkinson disease (PD) medication in advanced PD on neuropsychological performance, psychiatric symptoms, impulsivity and the quality of life. In the 4-year period 27 patients with advanced PD, scheduled for deep brain stimulation (DBS) surgery (N=27, mean age: 58.9±7.1, disease duration: 10.0 years±4.2) were examined preoperatively. We hypothesized that a high dosage of PD medication or current use of dopamine agonists affect cognitive functioning and psychiatric wellbeing.We performed two subgroup analyses with low versus high levodopa-equivalent Dosage (LED) medication and without versus with dopaminagonistic medication.The neuropsychological testing revealed significant differences in the verbal learn- and memory-test (VLMT) during the learning passage (U=36.500, Z=- 2.475, p=0.012) and in the subtest of the semantic fluency of Regensburg verbal fluency test (RWT) (t(25)=- 2.066, p=0.049) with better results for patients without dopaminagonistic medication. Pearson correlation analyses of LED in correlation with the clinical and cognitive dependent variables showed a significant higher PANSS total score in patients with higher LED medication (r=0.491, p=0.009). In addition, lower LED treatment was associated with significant higher scores in the impulsivity perseverance subtest (r=- 0.509, p=0.008).In conclusion, we found lower LEDs to be correlated with a better perseverance in the impulsivity test and additional treatment with a dopamine agonist influenced some verbal learning tasks and the PANSS total score in patients with advanced PD. This should be considered prior to DBS surgery.
Keyword(s): Humans (MeSH) ; Parkinson Disease: drug therapy (MeSH) ; Parkinson Disease: psychology (MeSH) ; Parkinson Disease: complications (MeSH) ; Parkinson Disease: therapy (MeSH) ; Deep Brain Stimulation (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Female (MeSH) ; Neuropsychological Tests (MeSH) ; Aged (MeSH) ; Antiparkinson Agents: therapeutic use (MeSH) ; Quality of Life (MeSH) ; Dopamine Agonists: therapeutic use (MeSH) ; Levodopa: therapeutic use (MeSH) ; Cognition: drug effects (MeSH) ; Antiparkinson Agents ; Dopamine Agonists ; Levodopa
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |